Literature DB >> 17516113

Radioembolization with 90Y microspheres: angiographic and technical considerations.

Robert J Lewandowski1, Kent T Sato, Bassel Atassi, Robert K Ryu, Albert A Nemcek, Laura Kulik, Jean-Francois Geschwind, Ravi Murthy, William Rilling, David Liu, Lourens Bester, Jose Ignacio Bilbao, Andrew S Kennedy, Reed A Omary, Riad Salem.   

Abstract

The anatomy of the mesenteric system and the hepatic arterial bed has been demonstrated to have a high degree of variation. This is important when considering pre-surgical planning, catheterization, and trans-arterial hepatic therapies. Although anatomical variants have been well described, the characterization and understanding of regional hepatic perfusion in the context of radioembolization have not been studied with great depth. The purpose of this review is to provide a thorough discussion and detailed presentation of the angiographic and technical aspects of radioembolization. Normal vascular anatomy, commonly encountered variants, and factors involved in changes to regional perfusion in the presence of liver tumors are discussed. Furthermore, the principles described here apply to all liver-directed transarterial therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516113     DOI: 10.1007/s00270-007-9064-z

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  59 in total

Review 1.  Radioembolization for primary and metastatic liver cancer.

Authors:  Khairuddin Memon; Robert J Lewandowski; Laura Kulik; Ahsun Riaz; Mary F Mulcahy; Riad Salem
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

2.  Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome.

Authors:  Sabeen Dhand; Ramona Gupta
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

Review 3.  Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies.

Authors:  Khairuddin Memon; Robert J Lewandowski; Ahsun Riaz; Riad Salem
Journal:  Curr Treat Options Oncol       Date:  2012-09

Review 4.  Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Stacey M Stein; Hyun S Kim
Journal:  Liver Cancer       Date:  2019-01-16       Impact factor: 11.740

Review 5.  Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers.

Authors:  Samdeep K Mouli; Ramona Gupta; Neil Sheth; Andrew C Gordon; Robert J Lewandowski
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

Review 6.  Radioembolization of hepatic tumors.

Authors:  Andrew Kennedy
Journal:  J Gastrointest Oncol       Date:  2014-06

7.  Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Jon Bell; Carlo Chiesa; Kirk Fowers; Bonnie Hamilton; Joseph Herman; S Cheenu Kappadath; Thomas Leung; Lorraine Portelance; Daniel Sze; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-16       Impact factor: 9.236

Review 8.  Frontiers of therapy for hepatocellular carcinoma.

Authors:  Michael Heller; Neehar D Parikh; Nicholas Fidelman; Dawn Owen
Journal:  Abdom Radiol (NY)       Date:  2021-04-10

Review 9.  Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma.

Authors:  Zersenay Alem; Timothy E Murray; Csilla Egri; John Chung; David Liu; Khaled M Elsayes; Silvia D Chang; Alison Harris
Journal:  Abdom Radiol (NY)       Date:  2021-04-28

10.  Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension.

Authors:  Nerea Fernández-Ros; Nuno Silva; Jose Ignacio Bilbao; Mercedes Iñarrairaegui; Alberto Benito; Delia D'Avola; Macarena Rodriguez; Fernando Rotellar; Fernando Pardo; Bruno Sangro
Journal:  HPB (Oxford)       Date:  2013-03-27       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.